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Introduction
Resistance of tumour cells to different antineoplastic agents is
a major problem in chemotherapy treatment. The spectrum of
antineoplastic drugs that can be used is very wide such as
methotrexate, cisplatin, mitomycin C, bleomycin, etc.
Laboratory studies can evaluate the potency of these drugs
by different methods and cellular models. We used cisplatin
as a drug model due to its mechanism of action. It forms
cytotoxic adducts with the DNA dinucleotide d(pGpG),
inducing intra-strand crosslinks, leading to apoptosis. The
mechanisms involved in cisplatin resistance include the
decrease of the cellular entry of the drug and increase of the
extrusion, activation of detoxification systems, alteration of
cell targets, increase in DNA repair, alteration of apoptosis
and alteration of the oncogenes expression. The budding
yeast (S. cerevisiae) is an excellent eukaryotic model to study
the antineoplastic drugs effects, due to the well-characterized
metabolic and genetic characteristics and the conserved
similarity in molecular mechanisms with other species including
human cells.
Objectives
The aim of this work is to study the effect of cisplatin on S.
cerevisiae cells and select cisplatin-resistant cells of this
organism as a model of study of resistance to antineoplastic
drugs.
Methodology
Yeast strain and culture medium
The experiments were carried out with the haploid yeast
strain S. cerevisiae WS8105-1C (genotype: MATalpha, ade2,
arg4-17, trp1-289, ura3-52). Yeast cells were grown in a
solid medium of YPD for the cytotoxicity assay, and in a liquid
medium of YPD for selecting cisplatin-resistant cells of this
organism.
Chemicals
The antineoplastic drug used was cisplatin. The doses used
were 0, 50, 100, 300, 500, 700 and 900 μg/ml for the
cytotoxicity assay and 300 μg/ml for selecting cisplatin-
resistant cells.
Experimental protocol
Cytotoxicity test: cells were added to test tubes with different
doses of cisplatin and they were completed with sterile water.
Then, the tubes were cultured during 24 hours at 30°C and
cells washed twice with sterile water. For drop test assay, six
10-fold serial dilutions from each sample were prepared and
five-microliter aliquots of each dilution were spotted onto YPD
plates. The same test was carried out to the resistant strain
WS8105-1C-R300cisPt.
Resistance selection: cells were added to test flask with 8 ml
of liquid medium of YPD and 300 μg/ml of cisplatin. Then,
the flask were cultured during 10 days in orbital shaking at
300 rpm and at 30°C. Next, a reseeding was carried out in
another test flask with the same conditions. The process was
carried out six times (six cycles). The OD600 was measured
daily.
Results and conclusions
TheThe cytotoxicity curve for cisplatin obtained by drop test showed that the surviving fraction decreased gradually as cisplatin dose increased in
the wild strain S. cerevisiae (WT). The ID50 and ID90 values obtained were 90 μg/ml and 300 μg/ml, respectively.
When exposed the WT to 300 μg/ml of cisplatin, in the different resistance cycles, it was obtained that in cycle 1 and for a N value of 9x107
cells/ml the stationary phase was reached on day 6. However, for cycles 3-6 and for an average value of N of 2.25x108 cells/ml the stationary
phase was reached around day 4.
In addition, there was a delay in cell growth. So, for a value of N of 9x107 cells/ml cycle1 presented a time of 6 days, cycle 2 of 3 days, cycle 3
and 4 of 1.75 days, cycle 5 of 3 days, and cycle 6 of 2.5 days. Thus it was observed that for the same value of N, as more cycles were done, the
time to reach that value decreased.
The 6 cycles lasted 80 days. The most relevant were cycle 1, which for a N value of 9x107 cells/ml presented a time of 6 days, cycle 3 that for a
N value of 2.1x108 cells/ml presented a time of 30 days and cycle 4 that for a N value of 2.45 x108 cells/ml it presented a time of 40 days.
To confirm that the yeast acquired resistance, the same cytotoxicity test was carried out. The decrease of the surviving fraction in the WT was
clearly greater than in strain WS8105-1CR300cisPt (resistant strain). In addition, in the resistant strain the ID50 and ID90 values obtained were
224 μg/ml (2.5 times more resistant with respect to the WT) and 735 μg/ml (2.78 times more resistant with respect to the WT), respectively.
In conclusion, at first cells were sensitive to the drug and had low cell growth, but when cells were subjected to drug concentration in each cycle, they
developed resistance mechanisms that allowed them to survive, grow and divide in the presence of cisplatin, thus increasing cell growth. In addition,
it could also be observed that the stationary phase was reached in a shorter time. These facts indicate the acquisition of resistance.
Therefore, the present results and model could be useful for future antineoplastic drugs studies.
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